MicroRNAs: New ways to block tumor angiogenesis?

Journal of Hepatology

Volumn 57, Issue 3, 2012, Pages 490-491

  Toffanin, Sara ^a,b   Sia, Daniela ^b,c   Villanueva, Augusto ^c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Angiogenesis; Hepatocellular carcinoma; MicroRNAs; Targeted therapies

Indexed keywords

CEDIRANIB; HEPATOMA DERIVED GROWTH FACTOR; INTERFERON; MICRORNA; MICRORNA 122; MICRORNA 214; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; EDITORIAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICRORNAS; NEOPLASM RECURRENCE, LOCAL;

EID: 84865112353     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.06.005     Document Type: Editorial

References (18)

1. A.X. Zhu, D.G. Duda, D.V. Sahani, and R.K. Jain HCC and angiogenesis: possible targets and future directions Nat Rev Clin Oncol 8 5 2011 292 301
2. A. Villanueva, and J.M. Llovet Targeted therapies for hepatocellular carcinoma Gastroenterology 140 5 2011 1410 1426
3. T.C. Shih, Y.J. Tien, C.J. Wen, T.S. Yeh, M.C. Yu, and C.H. Huang MicroRNA-214 downregulation contributes to tumor angiogenesis via inducing secretion of hepatoma-derived growth factor in human hepatoma J Hepatol 57 2012 584 591
4. S. Toffanin, Y. Hoshida, A. Lachenmayer, A. Villanueva, L. Cabellos, and B. Minguez MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a Gastroenterology 140 5 2011 1618-28.e16
5. M. Yamakuchi, C.D. Lotterman, C. Bao, R.H. Hruban, B. Karim, and J.T. Mendell P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis Proc Natl Acad Sci U S A 107 14 2010 6334 6339
6. A. Cimmino, G.A. Calin, M. Fabbri, M.V. Iorio, M. Ferracin, and M. Shimizu MiR-15 and miR-16 induce apoptosis by targeting BCL2 Proc Natl Acad Sci U S A 102 39 2005 13944 13949 (Pubitemid 41377683)
7. G. Alpini, S.S. Glaser, J.P. Zhang, H. Francis, Y. Han, and J. Gong Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer J Hepatol 55 6 2011 1339 1345
8. J.H. Fang, H.C. Zhou, C. Zeng, J. Yang, Y. Liu, and X. Huang MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression Hepatology 54 5 2011 1729 1740
9. E. Penna, F. Orso, D. Cimino, E. Tenaglia, A. Lembo, and E. Quaglino MicroRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C EMBO J 30 10 2011 1990 2007
10. T. Ueda, S. Volinia, H. Okumura, M. Shimizu, C. Taccioli, and S. Rossi Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis Lancet Oncol 11 2 2010 136 146
11. C.A. Gebeshuber, K. Zatloukal, and J. Martinez MiR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis EMBO Rep 10 4 2009 400 405
12. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 2008 378 390
13. A. Villanueva, and J.M. Llovet Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib Clin Cancer Res 18 7 2012 1824 1826
14. Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol 2011.
15. J.L. Rubenstein, J. Kim, T. Ozawa, M. Zhang, M. Westphal, and D.F. Deen Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2 4 2000 306 314
16. H.L. Janssen, H.W. Reesink, S. Zeuzem, E. Lawitz, M. Rodriguez-Torres, and A. Chen A randomized, double-blind, placebo (PLB) controlled safety and anti-viral proof of concept study of miravirsen (MIR), an oligonucleotide targeting miR-122, in treatment naive patients with genotype 1 (GT1) chronic HCV infection Hepatology 54 2011 1430A [abstract LB-6]
17. J. Kota, R.R. Chivukula, K.A. O'Donnell, E.A. Wentzel, C.L. Montgomery, and H.W. Hwang Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model Cell 137 6 2009 1005 1017
18. J. Ji, J. Shi, A. Budhu, Z Yu, M. Forgues, and S. Roessler MicroRNA expression, survival, and response to interferon in liver cancer N Engl J Med 361 15 2009 1437 1447